Onkologija (Nov 2022)

Oligometastatic cancer

  • Ivica Ratoša,
  • Karmen Stanič,
  • Tanja Ovčariček,
  • Ajra Šečerov Ermenc,
  • Janka Čarman,
  • Blaž Grošelj,
  • Staša Jelerčič,
  • Peter Korošec,
  • Manja Kobav,
  • Marko Kokalj,
  • Gaber Plavc,
  • Miha Oražem,
  • Helena Barbara Zobec Logar

DOI
https://doi.org/10.25670/oi2022-009on
Journal volume & issue
Vol. 26, no. 2

Abstract

Read online

Oligometastatic disease (OMD) is a stage between locally advanced disease and polymetastatic disease, a group of diseases that are used interchangeably based on treatment history, ongoing treatment status, and imaging findings. The diagnosis of OMD is based on imaging because, as of yet, we are not aware of any specific biomarkers that would enable us to recognize patients with a low disease burden. In recent years, there has been an increasing interest in optimizing the treatment of OMD, owing mostly to the promising outcomes of combining local and systemic treatment. For the first time, the prospect of achieving long-term cures or possibly curing these individuals was established using this form of treatment. The standard name of OMD subgroups allows for the comparison of diverse circumstances in everyday clinical work, as well as the classification for clinical study comparability.

Keywords